Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_assertion type Assertion NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_head.
- NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_assertion description "[The results indicated that ILK might be used as a potential therapeutic strategy to combat multi-drug resistance through blocking PI3K-Akt and MAPK-ERK pathways in human gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_provenance.
- NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_assertion evidence source_evidence_literature NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_provenance.
- NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_assertion SIO_000772 23317227 NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_provenance.
- NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_assertion wasDerivedFrom befree-2016 NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_provenance.
- NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_assertion wasGeneratedBy ECO_0000203 NP1043472.RAztyjphYwU9omQoXcfo2Kzk4SxL6sw5MOnzboFa4UoLs130_provenance.